Showing results (291-300 of 311) with videos related to
Sort By:
Pageof 32
Acta Physiologica (Oxford, England)|January 23, 2018
Four days of simulated shift work reduces insulin sensitivity in humansR Bescos, M J Boden, M L Jackson, et al.The Pharmacogenomics Journal|July 6, 2016
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancerA Musolino, N Naldi, M V Dieci, et al.Neuromuscular Disorders : NMD|February 14, 2017
PGM1 deficiency: Substrate use during exercise and effect of treatment with galactoseN C Voermans, N Preisler, K L Madsen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancerM Venturini, A Michelotti, L Del Mastro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-OvestP F Conte, M Bruzzone, F Carnino, et al.Cancer Treatment Reviews|January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical reviewF Miglietta, A Fabi, D Generali, et al.British Journal of Cancer|July 30, 2005
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II studyP F Conte, S Donati, A Gennari, et al.Translational Psychiatry|July 6, 2021
Cerebral small vessel disease burden and longitudinal cognitive decline from age 73 to 82: the Lothian Birth Cohort 1936O K L Hamilton, S R Cox, J A Okely, et al.Gynecologic Oncology|June 1, 1997
Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord OvestM Bruzzone, A Rubagotti, A Gadducci, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant studyV Guarneri, M V Dieci, G Bisagni, et al.Pageof 32